Nucleai aims to Improve cancer diagnostics making it accurate, effective, accessible and efficient in order to treat patients better by using Machine Learning, Deep Learning, and Machine Vision technology. The company was founded by highly experienced Artificial Intelligence experts, who previously led an AI and Data Science R&D department and is supported by leading pathologists in Israel and the US such as the former president of the CAP (College of American Pathologists) Jared Schwartz, MD. Ph.D., and Mark Valasek, MD. Ph.D.(UCSD). Nucleai is Backed by top-tier Israeli VC (@Vertex Ventures and @Grove Ventures) and private investors (Nir Kalkstein | Medial EarlySign and Brian Cooper | Retalix). Nucleai is currently developing applications for prostate, gastro and breast-related indications.